In brief On 19 July 2022, the Ministry of Health of Ukraine (MOH) approved Order No. 1251 (“Order”). The Order enables the implementation of Law No. 2271-IX (“Law”) aimed at preventing the turnover of pharmaceuticals manufactured in Russia or Belarus, or marketed by marketing authorization holders affiliated or otherwise related to companies with pharmaceutical manufacturing in these countries. On 29 July 2022, the Order became effective. Thus, from 29 July 2022, the Law became applicable.…

On 8 June 2022, law No. 2271-IX (“Law”) became effective. This Law expects to prevent the turnover of pharmaceuticals manufactured in Russia or Belarus, or marketed by marketing authorization holders affiliated or otherwise related to companies with pharmaceutical manufacturing in these countries. For more details on the draft of this law, please refer to our dedicated legal alert. As a next step, to enable the implementation of the Law, the Ministry of Health of Ukraine…

On 22 May 2022, the Parliament of Ukraine adopted draft law No. 7313 (“Draft Law”) aiming to prevent the turnover of pharmaceuticals manufactured in Russia or Belarus, or marketed by marketing authorization holders affiliated or otherwise related to companies with pharmaceutical manufacturing in these countries. To become effective, the Draft Law would need to be signed by the president of Ukraine and published in the official gazette. The Draft Law will come into force on…

On 3 May 2022, the parliament of Ukraine adopted in the first reading the draft law No. 7313 (“Draft Law”), aiming to prevent the turnover of pharmaceuticals manufactured in Russia or Belarus, or marketed by marketing authorization holders with ties to pharmaceutical manufacturing in these countries. The restrictions set forth in the Draft Law are discussed below. Cancellation or refusal in marketing authorization Based on the current wording of the Draft Law, the Ministry of…